Hidenori Ochi Selected Research

daclatasvir

12/2018	Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.
4/2018	Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.
1/2018	Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
4/2017	Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
4/2017	Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
3/2017	Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
1/2017	Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.
1/2017	The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
12/2016	Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing.
8/2016	Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hidenori Ochi Research Topics

Disease

45	Infections 12/2018 - 11/2006
38	Chronic Hepatitis C 12/2018 - 05/2009
15	Chronic Hepatitis B 01/2019 - 11/2006
14	Liver Cirrhosis (Hepatic Cirrhosis) 08/2020 - 09/2010
11	Hepatocellular Carcinoma (Hepatoma) 01/2019 - 01/2012
10	Fibrosis (Cirrhosis) 04/2018 - 09/2010
9	Non-alcoholic Fatty Liver Disease 08/2020 - 12/2010
9	Hepatitis C 04/2017 - 04/2011
6	Neoplasms (Cancer) 01/2018 - 01/2013
5	Hepatitis B 12/2018 - 11/2006
5	Liver Diseases (Liver Disease) 01/2018 - 09/2010
5	Type 2 Diabetes Mellitus (MODY) 01/2018 - 05/2012
5	Anemia 06/2017 - 10/2010
4	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 05/2017 - 08/2012
4	Insulin Resistance 02/2017 - 12/2014
3	Atrial Fibrillation 01/2019 - 12/2016
3	Hepatitis 12/2018 - 10/2013
2	Brugada Syndrome 01/2022 - 12/2017
2	Chronic Hepatitis (Chronic Active Hepatitis) 12/2018 - 03/2017
2	Hepatic Encephalopathy 03/2018 - 07/2013
2	Thrombosis (Thrombus) 01/2018 - 06/2015
2	Inflammation (Inflammations) 01/2018 - 09/2010
2	Ventricular Fibrillation 01/2016 - 04/2013
2	Disease Progression 03/2015 - 12/2007
2	Persistent Infection 01/2013 - 05/2009
2	Viremia 09/2011 - 11/2005
1	Esophagitis 01/2021
1	Tachycardia (Tachyarrhythmias) 01/2021
1	Atrial Remodeling 10/2018
1	Necrosis 01/2018
1	Tics (Tic) 01/2018

Drug/Important Bio-Agent (IBA)

44	InterferonsIBA 01/2019 - 05/2007
31	Ribavirin (Virazole)FDA LinkGeneric 12/2018 - 01/2010
14	Antiviral Agents (Antivirals)IBA 01/2019 - 01/2012
13	daclatasvirIBA 12/2018 - 01/2014
12	asunaprevirIBA 12/2018 - 01/2015
7	telaprevirIBA 06/2016 - 07/2011
6	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2012
6	Alanine Transaminase (SGPT)IBA 01/2018 - 06/2009
5	AntigensIBA 01/2019 - 10/2011
5	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2019 - 01/2017
5	Proteins (Proteins, Gene)FDA Link 12/2018 - 11/2006
5	Glucose (Dextrose)FDA LinkGeneric 01/2018 - 03/2014
5	Aspartate Aminotransferases (Aspartate Transaminase)IBA 12/2014 - 12/2010
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2013
4	nasIBA 08/2020 - 07/2013
4	NucleotidesIBA 01/2019 - 10/2013
4	NucleosidesIBA 01/2019 - 05/2007
4	SofosbuvirIBA 12/2018 - 04/2017
4	DNA (Deoxyribonucleic Acid)IBA 12/2018 - 05/2014
4	RNA (Ribonucleic Acid)IBA 04/2018 - 07/2012
4	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 05/2017 - 08/2012
4	SimeprevirIBA 03/2017 - 06/2016
4	Interferon LambdaIBA 09/2015 - 02/2011
3	ledipasvirIBA 12/2018 - 04/2017
3	entecavir FDA Link 12/2018 - 12/2007
3	Hemoglobins (Hemoglobin)IBA 06/2017 - 06/2011
3	Complementary DNA (cDNA)IBA 05/2017 - 01/2011
3	Insulin (Novolin)FDA Link 02/2017 - 01/2015
3	Triglycerides (Triacylglycerol)IBA 03/2016 - 07/2013
3	HLA-DP Antigens (HLA-DP)IBA 12/2015 - 05/2009
3	Pharmaceutical PreparationsIBA 11/2015 - 11/2006
3	Lamivudine (Epivir)FDA Link 05/2007 - 11/2005
2	Genetic Markers (Genetic Marker)IBA 01/2021 - 01/2018
2	sofosbuvir drug combination ledipasvirIBA 04/2018 - 11/2017
2	ChemokinesIBA 01/2018 - 01/2011
2	HMGB1 Protein (HMG1)IBA 01/2018 - 01/2018
2	Sorafenib (BAY 43-9006)FDA Link 01/2018 - 01/2018
2	Hepatitis B e AntigensIBA 01/2018 - 10/2013
2	danaparoid (Orgaran)FDA Link 01/2018 - 06/2015
2	Circulating Tumor DNAIBA 01/2018 - 09/2015
2	CytokinesIBA 01/2018 - 09/2010
2	Immunosuppressive Agents (Immunosuppressants)IBA 04/2017 - 06/2016
2	Protease Inhibitors (Protease Inhibitor)IBA 12/2016 - 11/2014
2	AdiponectinIBA 01/2016 - 01/2015
2	HLA-DQ Antigens (HLA-DQ)IBA 01/2013 - 10/2011
2	Guanosine Triphosphate (GTP)IBA 07/2012 - 09/2010
2	Amino Acids FDA Link 09/2011 - 02/2011
2	PyrophosphatasesIBA 06/2011 - 10/2010
2	Inosine Triphosphate (ITP)IBA 06/2011 - 10/2010
2	lipoarabinomannan (LAM)IBA 12/2007 - 05/2007
1	1- (5- (2- fluorophenyl)- 1- (pyridin- 3- ylsulfonyl)- 1H- pyrrol- 3- yl)- N- methylmethanamineIBA 01/2021
1	Histidine (L-Histidine)FDA Link 01/2019
1	Calcium-Binding ProteinsIBA 01/2019
1	Ritonavir (Norvir)FDA Link 12/2018
1	Interleukin-8 (Interleukin 8)IBA 12/2018
1	ombitasvirIBA 12/2018
1	paritaprevirIBA 12/2018
1	Fatty Acids (Saturated Fatty Acids)IBA 02/2018
1	Immunoglobulin G (IgG)IBA 02/2018
1	Warfarin (Coumadin)FDA LinkGeneric 01/2018
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018
1	Bevacizumab (Avastin)FDA Link 01/2018

Therapy/Procedure

53	Therapeutics 01/2019 - 05/2009
7	Liver Transplantation 04/2017 - 11/2011
3	Drug Therapy (Chemotherapy) 01/2018 - 01/2018
3	Drug Tapering 11/2016 - 10/2010
2	Surgical Portasystemic Shunt (Portosystemic Shunt) 03/2018 - 07/2013
1	Catheter Ablation 01/2019
1	Retreatment 04/2018